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How did the study come about?
Dissatisfaction has been voiced over recent decades concerning
the lack of a relevant cardiovascular disease (CVD) scoring
system for European populations. Recently this deficiency has
been repaired with the publication of SCORE,1 although
nonfatal events are still not catered for. In addition, the entire
sequence of the human genome has recently been published.2
Common chronic diseases, such as coronary heart disease
(CHD) and stroke, may have a strong genetic component. They
are, however, caused not by a single genetic defect but by the
interactions of many genetic and environmental factors. Hence,
they are often called complex, multifactorial diseases.
Moreover, the biological effects of common genetic variants are
likely to be small in magnitude; indeed, variants with large
biological effects tend to be rare, for example familial
hypercholesterolaemia. Investigators examining the genetic
background of complex, multifactorial diseases should,
therefore, realize that they are looking for interactions between
genetic variants with small, or at most moderate, effects. It is
obvious that the reliable detection of these effects requires large
sample sizes and abundant statistical power, which can be
achieved only in a large collaborative study using high-
throughput genotyping. It should be emphasized, however, that
moderate and even small effects can carry considerable public
health significance if the genetic variants in question are
common in the population. The remarkable success of the
Human Genome Project has been possible only through the
multinational collaboration of several research laboratories and
the open exchange of information through the Internet.
Developments in genetics open up new possibilities for the
prevention and treatment of chronic diseases, but to capitalize
on this potential, a better understanding of the significance of
genetic variation and the interactions of genetic variants with
environmental factors is needed.
Towards the end of the WHO MONICA Project3 it was
realized that a follow-up of the cohorts recruited by the project
would be ideal for exploring both issues mentioned above. This
follow-up project was established under the name MORGAM
(MONICA, Risk, Genetics, Archiving, and Monograph;
www.ktl.fi/morgam) and now also includes cohorts from non-
MONICA centres. It was initially funded under the Fourth
Framework Programme of the European Union. Two of its
components, archiving and monograph, have been completed.
This profile describes the remaining two, risk and genetics, both
of which are based on the pooling of prospective CVD cohorts.
For a subset of these cohorts DNA is available and central
collation, preparation and genotyping in a case–cohort setting
are well under way. Since 2002, these activities have become a
component of GenomEUtwin (www.genomeutwin.org), a
Network of Excellence for Genomics in Europe, funded under
the Fifth Framework Programme. Centres have recruited their
cohorts and organized the follow-up locally using their own
funding. MORGAM is pooling these cohorts, and the funding is
devoted to co-ordination, pooling of samples and data, quality
assessment and control, central preparation of DNA, and
laboratory analysis. Support for the participating centres is
through access to their own results, the return of surplus
prepared DNA, a modest subvention to support data prepara-
tion and sample handling, and attendance at an annual
workshop. MORGAM has a Coordinator (A.E.) who also chairs
the MORGAM Management Group, on which the participating
laboratories, the MORGAM Data Centre at the Finnish
National Public Health Institute (KTL) in Helsinki, and the
GenomEUtwin Coordinator are represented.
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What does MORGAM cover, and how has
this changed?
MORGAM was designed with the overall aim of eventually
studying a limited number of well-defined phenotypes and
several hundred genetic factors simultaneously by pooling the
risk-factor data collected in the MONICA cross-sectional
surveys, adding follow-up and genotyping, and including other
relevant cohorts.
The main objective of the risk-factor component of the study
is to assess the similarity of risk coefficients for the classic CVD
risk factors in different parts of Europe, between men and
women, and between age groups using large cohorts with
standardized baseline measurements and carefully validated
fatal and nonfatal CHD and stroke end-points. Furthermore, the
data will be used to derive European risk scores and to assess
the impact of socioeconomic and other factors for which data
are available in the cohorts.
The MORGAM genetic component, which employs a
case–cohort design, will provide a framework for the analysis of
the associations among genetic variants, risk-factor phenotypes,
and disease events. This could also allow an assessment of
gene–gene and gene–environment interactions. The iden-
tification of meaningful combinations of genotypes and envir-
onmental factors will rely heavily on the use of appropriate
mathematical models and statistical techniques. The main
objective of the genetic component is to determine statistically
significant combinations of single nucleotide polymorphisms
(SNPs) from the multitude of genotypic data which, in
combination with environmental factors and possible
intermediate quantitative phenotypes, are predictors of incident
CHD and stroke events and total mortality. We are particularly
interested in examining the interactions of polymorphisms
which are located along the same biological pathway. The
pathways of interest will be genotyped systematically so that
each known SNP with a frequency 1% will be considered.
Ultimately, on average –6 SNPs of each gene in the pathway will
be chosen for genotyping on the basis of comparative genomics,
linkage disequilibrium relationships, and the literature.
Additional objectives of the study for the participating
populations are to (i) estimate the genotype and allele frequencies;
(ii) assess the linkage disequilibrium relationships and haplotype
frequencies; (iii) determine the population-attributable risk
associated with the most common forms of adverse genotypes;
and (iv) examine the relationships between different genotypes
and risk-factor phenotypes. The main hypothesis of the genetic
component is that the variation in genes—for example, regulating
blood coagulation and/or inflammatory reaction and/or lipid
metabolism—is a determinant of CVD risk.
Statistical methods
Analysis of the follow-up data to assess the effect of classic risk-
factor phenotypes is being carried out using Cox’s proportional
hazards model. The adoption of a case–cohort design means that
multiple end-points can be studied and the prevalence of gene
polymorphism in different parts of Europe can be established.4
Statistical methods for the analysis of case–cohort data with
multiple end-points are being developed in MORGAM.
Moreover, new statistical approaches for analysing the
resultant wealth of genetic markers will also be developed.
Preliminary analysis of genotypic data will be carried out as
follows: estimation of the allele frequencies, estimation of
haplotypes, and application of data-mining methods to look for
patterns which are associated with the incidence of CVD. The
haplotype frequencies can be estimated using any of the
existing methods.5 Owing to the incompleteness of the data on
haplotypes, simultaneous estimation of haplotype frequencies
and the effect of haplotypes using an appropriate survival model
is needed, and tools for such analysis are being developed as
part of MORGAM.
The relationships between different genotypes, risk-factor
phenotypes, and disease end-points are being investigated and
will be analysed in the case–cohort setting. We also propose to
perform a systematic, structured analysis of the data using, for
example, the Bayesian approach to statistical inference, which
has recently been popularized in genetics. Lately, some of the
MORGAM team, as part of the ECTIM study, have developed 
a method taking into account not only the raw association
between a polymorphism and a phenotype but also the effects
of all polymorphisms which are in linkage disequilibrium with
it. They have elegantly demonstrated this for nine polymorph-
isms of the P-selectin gene by employing a new maximum
likelihood method.6 Detailed haplotype analysis confirmed the
protective effect of the P715 allele and revealed that two
asparagine codons were consistently associated with a higher
risk of myocardial infarction, but only when they shared the
same haplotype. Another statistical tool developed by the team
which appears promising in this respect is DICE (detection of
informative combined effects).7 This employs automated data-
mining to explore the effects of several polymorphisms or other
nongenetic covariates. It combines the advantages of regressive
approaches with data exploration tools, assesses interactions
between polymorphisms, and is efficient at evaluating the
spectrum of polymorphisms within a given biological system.
This is relevant because MORGAM is mainly concentrating its
efforts on biological systems.
Population stratification
Population stratification is theoretically an important problem
as it implies confounding due to population structure. This
could explain some of the inconsistencies observed in
association studies. The problem arises because an ‘admixture’
of groups of people with differing genotypes within a
population could lead to misleading results if they are unevenly
distributed between case and control groups.8 Obviously this is
of importance to MORGAM in view of the large range of
populations which are being included, and it has been suggested
that unless random samples are selected from one
homogeneous population, this effect is always a legitimate
cause for concern over positive findings in association studies,
except those which deliberately control for it. There are
essentially two population-based approaches for controlling for
the effect: Genomic control9 and structure assessment.10 The
problem is being actively addressed in MORGAM.
Ethical issues
MORGAM has developed a system for dealing with the
complexities of undertaking a multicentre study based on the
genotyping of cohorts in several European countries. Added to
these complexities was the fact that, when the project was
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originally funded, the European Commission had no specific
guidelines on the conduct of such studies. MORGAM has
developed a system wherein ethical approval must be obtained
from the local ethics committee and evidence of the
participants’ informed consent is required from each
participating centre. The only exception to this is when a
national ethics committee grants consent for fully anonymized
samples to be analysed outside the country in question. All
samples and data are processed anonymously. Because each
centre can have full access to its genotypic data on request, it is
left up to those centres to consult with their local ethics
committees before the data are fed back to participants, with the
caveat that such data have been generated for research
purposes only, and as such are liable to error. Therefore, all
results must be repeated on a fresh sample of the participant’s
DNA before any advice is given. In addition, a series of material
and data transfer agreements have been devised to cover such
exchanges (www.ktl.fi/morgam).
Further phenotypic study
MORGAM will study a large number of polymorphisms but
only a few well-standardized phenotypes. There are plans in
hand to measure a large number of phenotypes, which will be
employed to address the inflammatory hypothesis of CHD.
Who is included in the sample?
Cohorts of adequate size and the quality of the measurements
are critical both for the risk-factor component of the study and
for addressing the genetic hypotheses involving multiple
interactions. We are conducting a large multicentre study and
we are giving a high priority to the quality of the data and to
common polymorphisms in the participating populations. The
data come from the centres participating in MORGAM, which
are able to follow up their cohorts for CHD events, stroke, and
total mortality and most of which are also able to provide a DNA
sample. The cohorts are from Australia, Denmark, Finland,
France, Italy, Lithuania, Northern Ireland, Poland, Russia,
Scotland, Sweden, and Wales (Figure 1). Most of these are
representative samples of populations from geographically
defined areas (Table 1). There are several other potential
centres. To date, MORGAM has identified a total of 12 564
deaths from all causes, and 8916 CHD and stroke (fatal and
nonfatal) cases in a total cohort of 128 874 subjects. In 52 446
of these, for whom DNA is available, 2631 cases have been
validated. For cohorts in the genetic component, DNA from all
deaths and CVD cases and from a random sample of the full
cohort will be extracted and stored at the Department of
Molecular Medicine at KTL in Helsinki. The design of
MORGAM allows any positive findings to be confirmed in
multiple, independent populations.
How often have study participants been
followed up?
All the cohorts were examined once at baseline. The length of
the follow-up period varies between centres (Table 1), and
many centres will extend their follow-up of end-points in
future. The follow-up procedures vary between centres and are
summarized in Table 2.
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Figure 1 MORGAM participating centres
What has been measured?
Table 2 categorizes the data items collected or measured in
MORGAM. The details of the measurements, other than
genotypes, are described in the MORGAM Manual
(www.ktl.fi/morgam).
The DNA will be genotyped using up-to-date high-
throughput methods at KTL (mass spectrometry and DNA
array-based chips), at INSERM U525, Paris, and at the Royal
College of Surgeons, Dublin (mass spectrometry). The list of
genes considered for genotyping in the first phase is given in
Table 3. In Dublin, genes affecting platelets and thrombosis,
which have not been tested in other studies, and genes for
antioxidants will be studied. The Paris laboratory will initially
concentrate on the integrin system, employing advanced
laboratory techniques. The use of high-throughput centralized
laboratories will facilitate cost-effective analysis which will be
very sparing of DNA resources. In the near future several
hundred polymorphisms of candidate genes will be typed in
MORGAM. Thus, the genotyping will permit very powerful and
very challenging analyses. Where the amount of DNA is very
limited, whole genome amplification will be performed. In the
future, whole genome scans may be practicable in MORGAM.
So far a total of 109 000 genotypes have been processed.
Over the life of MORGAM the DNA requirements have
become increasingly frugal, so that at present a mere 10 µg of
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Table 1 Summary of MORGAM cohorts (as of June 30, 2004)
Size of
Cohorts Baseline cohorts
with survey Age group Size of with End of
Country Population Cohortsa DNA period at baseline cohorts DNA follow-up
Australia Newcastle 3 0 1983–94 24–70 5 873 0 1998
Denmark Glostrup 4 2 1982–94 25–74 6 914 4 281 1998
Finland ATBCb 1 1 1992–93 54–77 5 073 5073 1999
FINRISK/East 3 1 1982–92 24–65 13 192 3 013 2001
KIHDb 1 1 1991–93 46–65 1 038 1 038 2000
FINRISK/West 4 2 1982–92 24–65 7 647 2 986 2001
France PRIME/Lilleb 1 1 1991–93 49–64 2 633 2 633
PRIME/Strasbourgb 1 1 1991–93 49–64 2 612 2 612 5 years
PRIME/Toulouseb 1 1 1991–93 49–64 2 610 2 610
Italy CUORE/Brianza 4 4 1986–94 25–75 6 976 6 976 2002
CUORE/Friuli 4 2 1986–96 25–64 5 910 2 186 1998
CUORE/Rome 5 2 1982–96 18–81 1 0235 4 489 1998
CUORE/Naplesc 1 1 1993–97 29–72 5 062 5 062 1998
Lithuania Kaunas 3 0 1983–93 33–65 4 485 0 1998
Poland Krakow 3 0 1983–93 34–65 5 362 0 1998
Warsaw 3 0 1983–93 35–64 5 577 0 1998
Russia Novosibirsk 4 1 1983–95 23–65 11 438 3 273 1998
Sweden Northern Sweden 3 2 1986–94 24–74 5 094 3 469 1999
UK PRIME/Belfastb 1 1 1991–94 49–60 2745 2 745 5 years
Caerphillyb 1 0 1984–88 47–67 2 398 0 2000
Edinburgh 1 0 1986 25–65 1 299 0 2000
Glasgow 4 0 1986–95 25–75 5 536 0 2000
Scotland 1 0 1984–87 38–61 9165 0 2000
Total 57 23 128 874 52 446
a Number of cohorts examined at different times.
b Men only.
c Women only.
Table 2 Broad categories of data items collected in MORGAMa
Phase Data Measurements
Baseline Questionnaire Smoking, alcohol use, socioeconomic 
indicators, history of CHD, stroke, 
diabetes, family history of 
myocardial infarction 
and stroke, questions specific to 
women, ethnicity, availability of 
DNA, Rose questionnaire, 
Minnesota code
Measured Anthropometric measurements, blood 
pressure, cholesterol, triglycerides, 
fibrinogen, and SNP genotypesb
Follow-up Mortality Mostly by linkage to the national 
death register covering the whole 
country, in some centres by periodic 
follow-up by letter or linkage to 
health service register
Coronary and MONICA coronary and stroke event 
stroke events register, hospital discharge register, 
clinical event questionnaire, regional 
health information system
a Details of the data collected are available at www.ktl.fi/morgam.
b SNP genotypes are determined using a case–cohort design, for a random
sample of the study cohort and for cases who experienced coronary 
heart disease, stroke, death, with a history of cardiovascular disease at
baseline.
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Table 3 Primary analysis set of genes to be genotyped (as of
June 30, 2004)
Locuslink
Gene name Chromosome
Candidate genes related to lipids,
inflammation, and coagulation
ATP-binding cassette, subfamily ABCA1 9q31.1
A (ABC1), member 1
Beta2-adrenoceptor ADRB2 5q31–q32
Beta3-adrenoceptor ADRB3 8p12–p11.2
Angiotensin II receptor type 1 AGTR1 3q24
Apolipoprotein A-1 APOA1 11q23–24
Apolipoprotein A-2 APOA2 1q21–23
Apolipoprotein A-4 APOA4 11q23
Apolipoprotein A-5 APOA5 11q23
Apolipoprotein E APOE 19q13.2
Monocyte differentiation antigen CD14 CD14 5q31.1
Cholesteryl ester transfer protein CETP 16q21
Thrombin-activable fibrinolysis inhibitor CPB2 13q14.11
Cholesterol 7alpha-hydroxylase gene CYP7A1 8q11–q12
Coagulation factor X F10 13q34
Coagulation factor XII F12 5q33–qter
Coagulation factor XIII, alpha subunit F13A 6p25.3–p24.3
Prothrombin (coagulation factor 2) F2 11p11–q12
Thrombin receptor (F2R) F2R 5q13
Coagulation factor V F5 1q23
Coagulation factor VII F7 13q34
Fibrinogen, alpha chain FGA 4q28
Fibrinogen, beta chain FGB 4q28
Fibrinogen, gamma chain FGG 4q28
Forkhead box C2 (MFH-1, FOXC2 16q22–q24
mesenchyme forkhead 1)
Fucosyltransferase 1,3 FUT3 19p13.3
Familial combined hyperlipidemia 1 HYPLIP1 1q21–q23
Intercellular adhesion molecule 1 ICAM1 19p13.3–p13.2
Interleukin 10 IL10 1q31–q32
Interleukin 1 alpha IL1A 2q14
Interleukin 1 beta IL1B 2q14
Interleukin 6 IL6 7p21
Integrin alpha 2 ITGA2 5q23–q21
Integrin beta 3 ITGB3 17q21.32
Klotho KL 13q12
Lecithin-cholesterol acyltransferase LCAT 16q22.1
Lactase LCT 2q21
Low-density lipoprotein receptor LDLR 19p13.3
Hepatic lipase LIPC 15q21–q23
Mannose binding lectin LMAN1 18q21.3–q22
Melanocortin 4 receptor MC4R 18q22
5,10-Methylenetetrahydrofolate MTHFR 1p36.3
reductase
Microsomal triglyceride transfer protein MTP 4q24
Table 3 continued
Locuslink
Gene name Chromosome
Preproneuropeptide Y NPY 7p15.1
Phosphodiesterase 4D PDE4D 5q11.2
Tissue plasminogen activator PLAT 8p12
Phospholipid transfer protein PLTP 20q12–q13.1
Peroxisome proliferative activated PPARA 22q13.31
receptor, alpha
Peroxisome proliferator activator PPARD 6p21.2–p21.1
receptor, delta
Peroxisome proliferative activated PPARG 3p25
receptor, gamma
Protein C PROC 2q13–q14
RXR beta RXRB 6p21.3
Selectin E SELE 1q22–q25
Selectin L SELL 1q23–q25
Selectin P SELP 1q22–q25
Plasminogen activator inhibitor 1 SERPINE1 7q21.3–q22
Tissue factor pathway inhibitor TFPI 2q31–q32.1
Thrombomodulin THBD 20p12–c
Tumor necrosis factor alpha TNFA 6p21.3
Upstream transcription factor 1 USF1 1q22–23
Vascular cell adhesion molecule 1 VCAM1 1p32–p31
Pathogen response modulating genes
Chemokine (C-C) receptor 5 CCR5 3p21
Fucosyltransferase 2 FUT2 19q13.3
Natural resistance-associated SLC11A1 2q35
macrophage protein 1
Vitamin D (1,25 dihydroxyvitamin VDR 12q12–12q14
D3) receptor
Fc gamma, low affinity IIa receptor FCGR2A 1q21–q23
Interleukin 13 IL13 5q31
Toll-like receptor 4 TLR4 9q32–q33
IL12 receptor beta1 IL12RB1 19p13.1
Chemokine SDF1 (CXCL12) CXCL12 10q11.1
Chemokine receptor CCR2 CCR2 3p21
Candidate genes related to adhesion and
inflammation systems
Interleukin-18 IL18 11q22.2–q22.3
Interleukin-18 binding protein IL18BP
Interleukin-18 receptor 1 IL18R1 2q12
Interleukin 1-receptor antagonist IL1RN 2q14.2
Tumor necrosis factor receptor TNFRSF1A 12p13.2
superfamily, member 1A
Tumor necrosis factor receptor TNFRSF1B 1p36.3–36.2
superfamily, member 1B
Tumor necrosis factor-alpha-induced TNFAIP6 2
protein 6
Tumor necrosis factor ligand  TNFSF5 Xq26
superfamily, member 5 (CD40
ligand)
Glutathione peroxidase 1 GPX1 3p21.3
DNA is required. This reflects the rapid advances which have
been made in genotyping—requiring smaller and smaller
amounts of DNA; it is planned to keep a small aliquot of DNA
for analysis on a future high-throughput platform.
What is the attrition rate?
Particular attention has been paid to the coverage of the follow-
ups. Most of the centres have used national death registers covering
the whole country for the follow-up of mortality. However, the
geographic coverage of the follow-up of nonfatal events varies
between centres from the whole country to the study area. In most
centres, information about loss-to-follow-up is available.
What has MORGAM found?
The study is at an advanced stage. The baseline and follow-up
data have been centrally collected and genotyping is underway.
The first publications on the effects of the classic risk factors and
genetics on CHD and stroke are expected shortly.
What are the main strengths and weaknesses?
The strengths of the risk-factor cohort are manifestly its size,
standardized baseline and end-point assessment, the inclusion
of non-fatal cases, and the ability to compare different
geographic areas.
There is currently considerable interest in large population-
based genetic studies of complex diseases and the contribution
of environmental factors to their manifestation. MORGAM now
forms part of GenomEUtwin, and the rationale for this is that
various putative genetic traits identified in the twin research
approach which are relevant to CVD can be tested in the
MORGAM cohorts.11 Classic data from the Swedish Twin
Registry testify to the importance of genetics in CHD: the
relative hazard of one twin succumbing to the disease if the
other has died from the condition before the age of 55 years is
very significant, and this persists into the eighth decade.12
There may also be scope for investigating the level of risk
factors: in GenomEUtwin the heritability of both systolic and
diastolic blood pressure in monozygotic twins has been found to
be ~50%. Similarly, related twin studies have found that the
heritability of lipoprotein(a) is substantial, and, in smokers,
genetic factors determine 86% of the amount smoked.13
It is a central tenet in any discussion of the contribution of
polymorphism to complex disease that the cumulative effects of
variants carrying a slight excess of risk, particularly when they
interact with environmental factors such as diet, contribute
more than rare, serious mutations at the population level. The
dominant condition of familial hypercholesterolaemia was,
until recently, pretty disastrous for the individual, but its
population-attributable risk was small.13 The complexities of
unravelling the genetic contribution of many polymorphisms to
the development of CVD may be huge in view of the several
hundreds which may be involved. The problem is that many of
the single polymorphisms found to a be related to a disease in
association do not pass the test of time, that is to say, further
study. There has been a spate of papers bringing researchers face
to face with this stark reality.13 However, there is hope: in an
excellent paper, Cardon and Bell state, ‘Despite their recognized
limitations, association studies represent an essential step in
advancing the field to [sic] the definition of disease-mediating
genetic variants.’14 They go on to observe that ‘Control
ascertainment can be improved by using a PROSPECTIVE
COHORT study. This requires a substantial collection of
individuals to be selected before the onset of disease and to be
followed under the same experimental protocol.’ And they
conclude that ‘When properly applied and interpreted, it is
likely that association will continue to provide an essential
component of the expanding arsenal needed to dissect and
characterize the genetic basis of common disease.’
There are a few other large population genomics research
projects currently running or at the planning stage: three of these
have come together with GenomEUtwin to form an interna-
tional consortium: Public Population Project in Genomics
(www.p3gonsortium.org/). The other partners are CART@GENE,
a Canadian venture which will initially recruit 1700 participants
beginning in Autumn 2004; the Estonian Genome Project, which
currently has 9000 participants; and UK Biobank, which aims to
recruit 500 000 volunteers but is still at a planning stage.15
The aim is to develop MORGAM further as an open,
collaborative research network. The risk scores for CHD and
stroke are at an advanced stage of analysis and genotyping is well
under way. As mentioned (‘How did the study come about?’),
participating centres receive a modest degree of financial
support, but the real benefit they enjoy is that MORGAM
genotypes their DNA samples for them. By its nature, MORGAM
can only standardize a limited number of phenotypes with
precision across the many cohorts; once a centre receives its
genotyping results it is free to relate them to whatever
phenotypes it may have measured locally. Moreover, MORGAM
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Table 3 continued
Locuslink
Gene name Chromosome
Interleukin 18 receptor accessory protein IL18RAP 2q12
Caspase 1 CASP1 11q22.2–q22.3
Interleukin-1 receptor, type 1 IL1R1 2q12
Interleukin-1 receptor, type 2 IL1R2 2q12-q22
Interleukin-1 receptor accessory protein IL1RAP 3q28
Interleukin 12A IL12A 3p12–q13.2
Interleukin 12B IL12B 5q31.1–q33.1
Interleukin 15 IL15 4q31
Lymphotoxin-alpha LTA 6p21.3
Selectin P ligand SELPLG 12q24
Integrin alpha-4 ITGA4 2q31–q32
Integrin alpha-V ITGAV 2q31
Integrin alpha-L ITGAL 16p11.2
Integrin alpha-X ITGAX 16p11.2
Integrin beta-1 ITGB1 10p11.2
Integrin beta-2 ITGB2 21q22.3
Intracellular adhesion molecule 2 ICAM2 17q23–q25
Intracellular adhesion molecule 3 ICAM3 19p13.3–p13.2
Platelet-endothelial cell adhesion PECAM1 17q23
molecule 1
Cadherin-15 CDH15 16q24.30
does not have a fixed closing date and will remain open to new
cohorts for which DNA is available and to considering innovative
research proposals, provided that appropriate ethical clearances
are in position. Frozen sera or plasma samples from subsets of
MORGAM cohorts may be used for additional phenotyping, in
particular to explore the inflammatory hypothesis for CHD.
It is possible to pool cohorts internationally, provided that
adequate quality assurance procedures are in place. These have
been meticulously developed within the MONICA Project over
the past two decades. It is only through drawing on the unique
resource developed by the MONICA Project that its individual
participating centres could adequately pool their data and
samples, which are potentially so important.
Can I get hold of the data? Where can I
find out more?
The data at present remain the property of the participating
centres, in conjunction with MORGAM. The primary way of
gaining access to the data is through collaboration with the
MORGAM Project. As mentioned (‘Ethical issues’), transfer of
data and samples is subject to a system of material and data
transfer agreements. Readers who wish to find out more should
visit the MORGAM website, where a list of MORGAM
publications is being assembled (www.ktl.fi/morgam).
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